Markstein R
J Pharmacol. 1985;16 Suppl 3:1-17.
Hydergine (co-dergocrine, ergoloid mesylates, dihydroergotoxine) is an ergot preparation which has been shown to be of value in the treatment of senile mental impairment. Results from biochemical in vitro investigations suggest that Hydergine interacts directly with subtypes of alpha-adrenoceptors, dopamine and serotonin receptors. For instance, in slices of rat cerebral cortex, it blocked noradrenaline-induced increase of cyclic AMP content and facilitated electrically evoked noradrenaline release which is consistent with antagonistic properties at postsynaptic alpha 1- and presynaptic alpha 2-adrenoceptors. Furthermore, Hydergine had mixed agonist/antagonist properties at postsynaptic D1 receptors mediating stimulation of adenylate cyclase, and at pre- and postsynaptic D2 receptors mediating inhibition of evoked dopamine and acetylcholine release in the rat striatum, respectively. Hydergine had also mixed agonist/antagonist properties at the serotonin-sensitive adenylate cyclase in the rat hippocampus and the presynaptic serotonin autoreceptors present on nerve terminals in the rat cortex. Based on these in vitro data, it is suggested that Hydergine influences central monoaminergic systems in a dualistic manner. On the one hand, it can compensate for a transmitter deficit in dopaminergic and serotoninergic systems, but at the same time, counteract a possible hyperactivity in the same transmitter systems. The noradrenergic systems may be affected in a similar way but by a different mechanism. In this latter system, Hydergine increased evoked noradrenaline release by blocking presynaptic alpha-adrenergic autoreceptors, but by a simultaneous blockade of postsynaptic alpha 1-adrenoceptors sets a ceiling effect to the noradrenergic stimulation. Thus, Hydergine might be able to counteract and prevent disturbances in the interplay between monoaminergic and other transmitter systems in the central nervous system. It is proposed that these multiple effects of Hydergine are in part responsible for its beneficial effects in senile mental impairment.
喜得镇(氢化麦角碱,甲磺酸双氢麦角毒碱)是一种麦角制剂,已被证明在治疗老年精神障碍方面具有价值。体外生化研究结果表明,喜得镇直接与α-肾上腺素能受体、多巴胺受体和5-羟色胺受体亚型相互作用。例如,在大鼠大脑皮层切片中,它能阻断去甲肾上腺素诱导的环磷酸腺苷含量增加,并促进电诱发的去甲肾上腺素释放,这与它对突触后α1-和突触前α2-肾上腺素能受体的拮抗特性一致。此外,喜得镇在介导腺苷酸环化酶刺激的突触后D1受体以及分别介导大鼠纹状体中诱发的多巴胺和乙酰胆碱释放抑制的突触前和突触后D2受体上具有混合激动剂/拮抗剂特性。喜得镇在大鼠海马体中对5-羟色胺敏感的腺苷酸环化酶以及大鼠皮层神经末梢上存在的突触前5-羟色胺自身受体也具有混合激动剂/拮抗剂特性。基于这些体外数据,有人提出喜得镇以二元方式影响中枢单胺能系统。一方面,它可以弥补多巴胺能和5-羟色胺能系统中的递质不足,但同时,抵消同一递质系统中可能的活动亢进。去甲肾上腺素能系统可能以类似方式但通过不同机制受到影响。在后者系统中,喜得镇通过阻断突触前α-肾上腺素能自身受体增加诱发的去甲肾上腺素释放,但通过同时阻断突触后α1-肾上腺素能受体对去甲肾上腺素能刺激产生上限效应。因此,喜得镇可能能够抵消和预防中枢神经系统中单胺能和其他递质系统之间相互作用的紊乱。有人提出喜得镇的这些多种作用部分是其对老年精神障碍有益作用的原因。